Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/a-2346-9840
Validation of the German version of the Asthma Impairment and Risk Questionnaire (AIRQ)
Validierung der deutschen Version des Asthma Impairment and Risk Questionnaires (AIRQ) Supported by: AstraZeneca Germany![](https://www.thieme-connect.de/media/pneumologie/EFirst/lookinside/thumbnails/10-1055-a-2346-9840-1.jpg)
Abstract
Background The Asthma Impairment and Risk Questionnaire (AIRQ), a 10-item, equally weighted, yes/no tool assessing symptom impairment and risk of exacerbations in patients with asthma aged ≥12 years, was developed and validated in a US patient population to evaluate varying levels of asthma control. This study aimed to validate the German language version of the AIRQ in patients aged ≥12 years with different levels of asthma control.
Methods A cross-sectional, observational, multi-centre study comprising a single visit was conducted in multiple specialised asthma centres and general practices in Germany. A total of 300 patients completed the following measures: 1) Patient Sociodemographic and Clinical Questionnaire, 2) AIRQ, 3) Asthma Control Test (ACT), and 4) Asthma Control Questionnaire (ACQ-6). Logistic regression analyses were conducted to assess the AIRQ score cut points with the greatest predictive validity in discriminating between different control levels relative to a standard of ACT plus prior-year exacerbations or ACQ-6 plus prior-year exacerbations.
Results The German version of the AIRQ demonstrated a robust capability to correctly identify well-controlled versus not well- or very poorly controlled (AUC values of 0.90 or higher) and well- or not well-controlled versus very poorly controlled asthma (AUC values of 0.89 or higher).
Conclusions The German version of the AIRQ is a suitable tool to identify adults with varying levels of asthma control, which in turn can help to accurately identify patients with uncontrolled asthma in clinical practice.
Zusammenfassung
Hintergrund Der Asthma Impairment and Risk Questionnaire (AIRQ), ein 10 Punkte umfassendes, gleichgewichtetes Ja/Nein-Tool zur Beurteilung der Symptombeeinträchtigung und des Risikos von Exazerbationen bei Patienten mit Asthma im Alter von ≥12 Jahren, wurde in einer US-amerikanischen Patientenpopulation entwickelt und validiert, unterschiedliche Grade der Asthmakontrolle zu bewerten. Ziel dieser Studie war es, die deutschsprachige Version des AIRQ bei Patienten im Alter von ≥12 Jahren mit unterschiedlichem Grad der Asthmakontrolle zu validieren.
Methoden Eine beobachtende, multizentrische Querschnittsstudie mit einem einzigen Besuch wurde in mehreren spezialisierten Asthmazentren und Allgemeinpraxen in Deutschland durchgeführt. Insgesamt 300 Patienten absolvierten die folgenden Maßnahmen: 1) Soziodemografischer und klinischer Patientenfragebogen, 2) AIRQ, 3) Asthmakontrolltest (ACT) und 4) Asthmakontrollfragebogen (ACQ-6). Logistische Regressionsanalysen wurden durchgeführt, um die Schnittpunkte des AIRQ-Scores mit der größten prädiktiven Validität bei der Unterscheidung zwischen verschiedenen Kontrollniveaus im Vergleich zu einem Standard aus ACT plus Exazerbationen des Vorjahres oder ACQ-6 plus Exazerbationen des Vorjahres zu ermitteln.
Ergebnisse Die deutsche Version des AIRQ zeigte eine robuste Fähigkeit, gut kontrolliertes von nicht gut oder sehr schlecht kontrolliertem Asthma (AUC-Werte von 0,90 oder höher) sowie gut oder nicht gut kontrolliertes von sehr schlecht kontrolliertem Asthma (AUC-Werte von 0,89 oder höher) korrekt zu unterscheiden.
Schlussfolgerungen Die deutsche Version des AIRQ ist ein geeignetes Instrument zur Identifizierung von Erwachsenen mit unterschiedlichem Grad der Asthmakontrolle, was wiederum dazu beitragen kann, Patienten mit unkontrolliertem Asthma in der klinischen Praxis akkurat zu identifizieren.
Publication History
Received: 19 March 2024
Accepted after revision: 16 May 2024
Article published online:
11 July 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Global Initiative for Asthma (GINA). The Global Strategy for Asthma Management and Prevention. 2022
- 2 Suruki RY, Daugherty JB, Boudiaf N. et al. The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA. BMC Pulm Med 2017; 17: 74
- 3 Sullivan PW, Slejko JF, Ghushchyan VH. et al. The relationship between asthma, asthma control and economic outcomes in the United States. J Asthma 2014; 51: 769-778
- 4 Fuhlbrigge AL, Adams RJ, Guilbert TW. et al. The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines. Am J Respir Crit Care Med 2002; 166: 1044-1049 DOI: 10.1164/rccm.2107057. (PMID: 12379546)
- 5 Murphy KR, Meltzer EO, Blaiss MS. et al. Asthma management and control in the United States: results of the 2009 Asthma Insight and Management survey. Allergy Asthma Proc 2012; 33: 54-64 DOI: 10.2500/aap.2011.32.3518. (PMID: 22309716)
- 6 Sastre J, Fabbri LM, Price D. et al. Insights, attitudes, and perceptions about asthma and its treatment: a multinational survey of patients from Europe and Canada. World Allergy Organ J 2016; 9: 13
- 7 Kritikos V, Price D, Papi A. et al. A multinational observational study identifying primary care patients at risk of overestimation of asthma control. NPJ Prim Care Respir Med 2019; 29: 43 DOI: 10.1038/s41533-019-0156-4. (PMID: 31804501)
- 8 Nathan RA, Sorkness CA, Kosinski M. et al. Development of the Asthma Control Test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113: 59-65 DOI: 10.1016/j.jaci.2003.09.008. (PMID: 14713908)
- 9 Juniper EF, O´Byrne PM, Guyatt GH. et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14: 902-907 DOI: 10.1034/j.1399-3003.1999.14d29.x. (PMID: 10573240)
- 10 Lee TY, Petkau J, Sadatsafavi M. Long-Term Natural History of Severe Asthma Exacerbations and Their Impact on the Disease Course. Ann Am Thorac Soc 2022; 19: 907-915 DOI: 10.1513/AnnalsATS.202012-1562OC. (PMID: 34797732)
- 11 Murphy KR, Chipps B, Beuther DA. et al. Development of the Asthma Impairment and Risk Questionnaire (AIRQ): A Composite Control Measure. J Allergy Clin Immunol Pract 2020; 8: 2263-2274.e5
- 12 Reibman J, Chipps BE, Zeiger RS. et al. Relationship Between Asthma Control as Measured by the Asthma Impairment and Risk Questionnaire (AIRQ) and Patient Perception of Disease Status, Health-Related Quality of Life, and Treatment Adherence. J Asthma Allergy 2023; 16: 59-72
- 13 Beuther DA, Murphy KR, Zeiger RS. et al. Asthma Impairment and Risk Questionnaire (AIRQ) Control Level Predicts Future Risk of Asthma Exacerbations. J Allergy Clin Immunol Pract 2022; 10: 3204-3212.e2
- 14 Pérez de Llano L, Martínez Moragón E, Entrenas LM. et al. Validation of the Asthma Impairment and Risk Questionnaire (AIRQ) in Spain: a useful tool to assess asthma control in adolescent and adult patients. J Investig Allergol Clin Immunol 2022; 33: 397-400
- 15 Altman DG. Practical Statistics for Medical Research. New York (US): CRC Press; 1990
- 16 National Heart, Lung, and Blood Institute. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. Published December 2020. Accessed May 05, 2021 at: https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates
- 17 Fuhlbrigge A, Marvel J, Electricwala B. et al. Physician-Patient Concordance in the Assessment of Asthma Control. J Allergy Clin Immunol Pract 2021; 9: 3080-3088.e3081
- 18 Matsunaga K, Hamada K, Oishi K. et al. Factors Associated with Physician-Patient Discordance in the Perception of Asthma Control. J Allergy Clin Immunol Pract 2019; 7: 2634-2641